Dyne Therapeutics (NASDAQ:DYN) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a research report report published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $55.00 target price on the stock.

DYN has been the topic of several other research reports. Chardan Capital boosted their target price on Dyne Therapeutics from $31.00 to $42.00 and gave the company a buy rating in a research note on Tuesday, May 21st. Stifel Nicolaus increased their target price on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a buy rating in a report on Friday, August 16th. Jefferies Financial Group raised their target price on shares of Dyne Therapeutics from $36.00 to $42.00 and gave the company a buy rating in a research report on Monday, May 20th. Guggenheim boosted their price target on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a buy rating in a research report on Thursday, August 15th. Finally, Oppenheimer restated an outperform rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of Buy and a consensus price target of $51.40.

Dyne Therapeutics Stock Down 1.8 %

Dyne Therapeutics stock opened at $33.03 on Wednesday. Dyne Therapeutics has a twelve month low of $6.40 and a twelve month high of $47.45. The company has a 50 day moving average of $41.58 and a 200-day moving average of $32.98. The stock has a market capitalization of $2.89 billion, a PE ratio of -8.32 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. Equities analysts anticipate that Dyne Therapeutics will post -2.96 EPS for the current fiscal year.

Insider Activity

In other news, insider Oxana Beskrovnaya sold 2,136 shares of the firm’s stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $31.34, for a total value of $66,942.24. Following the completion of the sale, the insider now directly owns 147,511 shares of the company’s stock, valued at $4,622,994.74. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, COO Susanna Gatti High sold 80,000 shares of the company’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $30.24, for a total value of $2,419,200.00. Following the transaction, the chief operating officer now owns 154,062 shares in the company, valued at approximately $4,658,834.88. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Oxana Beskrovnaya sold 2,136 shares of the stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $31.34, for a total transaction of $66,942.24. Following the completion of the transaction, the insider now directly owns 147,511 shares in the company, valued at $4,622,994.74. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 163,676 shares of company stock valued at $5,270,510. 20.77% of the stock is owned by company insiders.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors have recently made changes to their positions in DYN. Nisa Investment Advisors LLC lifted its holdings in Dyne Therapeutics by 904.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after purchasing an additional 669 shares during the last quarter. Wetzel Investment Advisors Inc. bought a new stake in shares of Dyne Therapeutics in the first quarter valued at about $28,000. Amalgamated Bank boosted its position in shares of Dyne Therapeutics by 39.9% in the second quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock valued at $99,000 after acquiring an additional 796 shares during the period. Ameritas Investment Partners Inc. grew its stake in shares of Dyne Therapeutics by 28.0% in the first quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock valued at $167,000 after acquiring an additional 1,291 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado bought a new position in Dyne Therapeutics during the second quarter worth about $203,000. Institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.